Cargando…

Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity

Basal-like breast cancer (BLBC) is an aggressive breast cancer subtype with features similar to the basal cells surrounding the mammary ducts. Treatment of patients with BLBC has been challenging due to the lack of well-defined molecular targets. Due to the clinical and pathological similarities of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xian, Tan, Ying, Cao, Xixi, Kim, Jin Ah, Chen, Tianmeng, Hu, Yiheng, Wexler, Matthew, Wang, Xiaosong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059019/ https://www.ncbi.nlm.nih.gov/pubmed/30046392 http://dx.doi.org/10.18632/oncotarget.25728

Ejemplares similares

HORMAD2 methylation‐mediated epigenetic regulation of gene expression in thyroid cancer
por: Lin, Qiuyu, et al.
Publicado: (2018)

Mouse HORMAD1 and HORMAD2, Two Conserved Meiotic Chromosomal Proteins, Are Depleted from Synapsed Chromosome Axes with the Help of TRIP13 AAA-ATPase
por: Wojtasz, Lukasz, et al.
Publicado: (2009)

HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance
por: Zong, Beige, et al.
Publicado: (2021)

HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance
por: Zong, Beige, et al.
Publicado: (2021)

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
por: El‐Botty, Rania, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Hormad1 Mutation Disrupts Synaptonemal Complex Formation, Recombination, and Chromosome Segregation in Mammalian Meiosis
por: Shin, Yong-Hyun, et al.
Publicado: (2010)

Evaluation of phototoxicity induced by the anticancer drug rucaparib
por: Mateos-Pujante, Alejandro, et al.
Publicado: (2022)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
por: Yubero, Alfonso, et al.
Publicado: (2022)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023)

Correction: Hormad1 Mutation Disrupts Synaptonemal Complex Formation, Recombination, and Chromosome Segregation in Mammalian Meiosis
por: Shin, Yong-Hyun, et al.
Publicado: (2011)

The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge
por: Temian, Daiana Cosmina, et al.
Publicado: (2018)

Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

Emerging treatment options for ovarian cancer: focus on rucaparib
por: Mariappan, Lavanya, et al.
Publicado: (2017)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells
por: Soung, Young Hwa, et al.
Publicado: (2014)

Correction: Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
por: Dal Molin, Graziela Z., et al.
Publicado: (2018)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
por: Wu, Maximillian S, et al.
Publicado: (2022)

Meiotic cohesins mediate initial loading of HORMAD1 to the chromosomes and coordinate SC formation during meiotic prophase
por: Fujiwara, Yasuhiro, et al.
Publicado: (2020)

Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance
por: Tarantino, Dalia, et al.
Publicado: (2022)

The cancer testes antigen, HORMAD1, limits genomic instability in cancer cells by protecting stalled replication forks
por: Herrera, Luis Reza, et al.
Publicado: (2023)

RNF40 epigenetically modulates glycolysis to support the aggressiveness of basal-like breast cancer
por: Prokakis, Evangelos, et al.
Publicado: (2023)

The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells
por: Gao, Yanzhe, et al.
Publicado: (2018)

Ectopically Expressed Meiosis-Specific Cancer Testis Antigen HORMAD1 Promotes Genomic Instability in Squamous Cell Carcinomas
por: Gantchev, Jennifer, et al.
Publicado: (2023)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
por: Curtin, Nicola J
Publicado: (2020)

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
por: Grechko, Nikolay, et al.
Publicado: (2021)

LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications
por: Han, Yoo Jane, et al.
Publicado: (2018)

Multi-color dSTORM microscopy in Hormad1(-/)(-) spermatocytes reveals alterations in meiotic recombination intermediates and synaptonemal complex structure
por: Koornneef, Lieke, et al.
Publicado: (2022)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
por: Saravi, Sayeh, et al.
Publicado: (2021)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
por: Zhang, Qilin, et al.
Publicado: (2023)

Aberrantly expressed HORMAD1 disrupts nuclear localization of MCM8–MCM9 complex and compromises DNA mismatch repair in cancer cells
por: Liu, Kang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vpn7v41c335f1rh8k5ebi6u2bq